We therefore hypothesized that a combination of the XPO1 inhibitor KPT-185 andselective mTORC1/2 dual inhibitor AZD-2014 would demonstrate synergistic inhibition of MCL cell growth by repressing prosurvival metabolism in this cancer. Here, XPO1 is linked to mantle cell lymphoma.